The Filing Desk

ANI Pharmaceuticals vs Tilray Brands

ANI Pharmaceuticals ANIP · Tilray Brands TLRY · Pharmaceuticals

Tilray Brands reported revenue of $916 million in fiscal 2026, about the same as ANI Pharmaceuticals' $883 million in fiscal 2025. ANI Pharmaceuticals' revenue grew 43.8% in its latest year, and Tilray Brands' grew 11.5%. ANI Pharmaceuticals had an operating margin of 12.6%, against -6.9% at Tilray Brands. Their fiscal years end in different months (December 31 and May 31), so the periods don't line up exactly.

Side by side

ANI PharmaceuticalsTilray Brands
Latest fiscal yearFY2025, Dec 31, 2025FY2026, May 31, 2026
Revenue$883M$916M
Revenue growth43.8%11.5%
Revenue growth a year, last 5 years33.5%12.3%
Gross margin—28.4%
Operating margin12.6%−6.9%
Net margin8.9%−13.3%
Free cash flow$171M—
Free cash flow margin19.4%—
Return on capital15.9%−3.4%
Net debt to EBITDA0.1x—
Dividends and buybacks$13M$0M
Change in diluted share count9.9%25.6%
Last close$69.13$2.07
P/E at the last close13.8×—
Insider trades, last 12 monthssold $13.6 millionbought $69,225, sold $232,879
Piotroski F-score6 of 83 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
ANI PharmaceuticalsTilray Brands
Operating margin
Percent of revenue
ANI PharmaceuticalsTilray Brands
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ANI PharmaceuticalsTilray Brands

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the ANI Pharmaceuticals and Tilray Brands pages.